港股创新药概念股午后走低，相关ETF跌约3%

Group 1 - The core viewpoint of the news is that Hong Kong's innovative pharmaceutical stocks experienced a decline, with notable drops in companies such as China Biologic Products, which fell over 7%, and others like Innovent Biologics, WuXi Biologics, and 3SBio, which dropped over 4% [1] - Several Hong Kong innovative pharmaceutical ETFs also saw a decline of approximately 3% due to market influences [1] Group 2 - Specific ETF performance includes: - Hong Kong Innovative Pharmaceutical ETF Fund (520700) at 1.859, down 3.03% - Hong Kong Innovative Pharmaceutical 50 ETF (513780) at 1.920, down 2.98% - Hong Kong Innovative Pharmaceutical ETF (520880) at 1.272, down 2.90% - Other ETFs also reported declines ranging from 2.55% to 2.98% [2] - Analysts noted that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with procurement amounts from January to May nearing the total expected for 2024, indicating the competitiveness of China's innovative drugs in the international market [2]